Finerenone, a new non-steroidal MRA with higher mineralocorticoid receptor selectivity, was shown to reduce albuminuria in a dose-dependent manner in a cohort of DKD patients treated with RAS blockade, with a small incidence of hyperkalemia (3%) [75]. The gene discussed is NR3C2; the disease is Hyperkalemia.